Author

Andra Kennah

Institution: Sanofi (United States)

Observed institution: Sanofi (United States)

OpenAlex ID: A5000355841

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)

2013 · Luis E. Raez, Edgardo S. Santos, et al. · Cancer Chemotherapy and Pharmacology · 11

Works count: 1

Citation count: 11

H-index: 1

I10-index: 1